View ValuationRossari Biotech 将来の成長Future 基準チェック /16Rossari Biotechは、12.9%と9%でそれぞれ年率12.9%で利益と収益が成長すると予測される一方、EPSはgrowで12.9%年率。主要情報12.9%収益成長率12.88%EPS成長率Chemicals 収益成長16.3%収益成長率9.0%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日21 Jul 2026今後の成長に関する最新情報Price Target Changed • Jan 20Price target decreased by 20% to ₹680Down from ₹851, the current price target is an average from 3 analysts. New target price is 34% above last closing price of ₹509. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₹25.10 for next year compared to ₹24.66 last year.Price Target Changed • Apr 21Price target decreased by 8.8% to ₹901Down from ₹988, the current price target is an average from 3 analysts. New target price is 30% above last closing price of ₹693. Stock is down 8.1% over the past year. The company is forecast to post earnings per share of ₹24.97 for next year compared to ₹23.67 last year.Price Target Changed • Sep 30Price target increased by 7.6% to ₹951Up from ₹884, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of ₹907. Stock is up 11% over the past year. The company is forecast to post earnings per share of ₹29.03 for next year compared to ₹23.67 last year.Price Target Changed • Jan 25Price target increased by 9.0% to ₹852Up from ₹782, the current price target is an average from 2 analysts. New target price is 9.7% above last closing price of ₹776. Stock is up 7.8% over the past year. The company is forecast to post earnings per share of ₹24.30 for next year compared to ₹19.46 last year.Price Target Changed • Oct 28Price target decreased by 8.4% to ₹782Down from ₹854, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of ₹756. Stock is down 16% over the past year. The company is forecast to post earnings per share of ₹23.78 for next year compared to ₹19.46 last year.Price Target Changed • Feb 07Price target decreased by 9.2% to ₹986Down from ₹1,086, the current price target is an average from 2 analysts. New target price is 44% above last closing price of ₹683. Stock is down 42% over the past year. The company is forecast to post earnings per share of ₹21.50 for next year compared to ₹17.81 last year.すべての更新を表示Recent updatesお知らせ • Jul 21Rossari Biotech Limited Approves Dividend for the Financial Year Ended 31 March 2026Rossari Biotech Limited at its Annual General Meeting held on July 20, 2026, approved dividend of INR 0.50 (25%) per Equity Share of the face value of INR 2 each for the Financial Year ended 31 March 2026.お知らせ • Jul 11Rossari Biotech Limited to Report Q1, 2027 Results on Jul 18, 2026Rossari Biotech Limited announced that they will report Q1, 2027 results at 12:08 PM, Indian Standard Time on Jul 18, 2026お知らせ • Jun 18Rossari Biotech Limited, Annual General Meeting, Jul 20, 2026Rossari Biotech Limited, Annual General Meeting, Jul 20, 2026, at 11:00 Indian Standard Time.Reported Earnings • Apr 29Full year 2026 earnings: EPS and revenues exceed analyst expectationsFull year 2026 results: EPS: ₹26.95 (up from ₹24.66 in FY 2025). Revenue: ₹24.2b (up 16% from FY 2025). Net income: ₹1.49b (up 9.4% from FY 2025). Profit margin: 6.2% (down from 6.6% in FY 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.5%. Earnings per share (EPS) also surpassed analyst estimates by 7.0%. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹513, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 28x in the Chemicals industry in India. Total loss to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹310 per share.お知らせ • Apr 19Rossari Biotech Limited to Report Q4, 2026 Results on Apr 27, 2026Rossari Biotech Limited announced that they will report Q4, 2026 results on Apr 27, 2026Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹447, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 26x in the Chemicals industry in India. Total loss to shareholders of 40% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹324 per share.Price Target Changed • Jan 20Price target decreased by 20% to ₹680Down from ₹851, the current price target is an average from 3 analysts. New target price is 34% above last closing price of ₹509. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₹25.10 for next year compared to ₹24.66 last year.Reported Earnings • Jan 18Third quarter 2026 earnings: EPS misses analyst expectationsThird quarter 2026 results: EPS: ₹5.92 (up from ₹5.73 in 3Q 2025). Revenue: ₹5.82b (up 14% from 3Q 2025). Net income: ₹327.7m (up 3.4% from 3Q 2025). Profit margin: 5.6% (down from 6.2% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 4.7%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Jan 10Rossari Biotech Limited to Report Q3, 2026 Results on Jan 17, 2026Rossari Biotech Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Jan 17, 2026Reported Earnings • Oct 16Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: ₹6.66 (up from ₹6.39 in 2Q 2025). Revenue: ₹5.88b (up 18% from 2Q 2025). Net income: ₹368.8m (up 4.4% from 2Q 2025). Profit margin: 6.3% (down from 7.1% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.7%. Earnings per share (EPS) also surpassed analyst estimates by 3.9%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Oct 07Rossari Biotech Limited to Report Q2, 2026 Results on Oct 15, 2025Rossari Biotech Limited announced that they will report Q2, 2026 results at 12:08 PM, Indian Standard Time on Oct 15, 2025Reported Earnings • Jul 21First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: EPS: ₹6.07 (down from ₹6.32 in 1Q 2025). Revenue: ₹5.45b (up 11% from 1Q 2025). Net income: ₹336.0m (down 3.7% from 1Q 2025). Profit margin: 6.2% (down from 7.1% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) exceeded analyst estimates by 12%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Jul 15Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 8.0% to ₹743. The fair value is estimated to be ₹596, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.6% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 54% in the next 2 years.お知らせ • Jul 11Rossari Biotech Limited to Report Q1, 2026 Results on Jul 19, 2025Rossari Biotech Limited announced that they will report Q1, 2026 results at 12:08 PM, Indian Standard Time on Jul 19, 2025Upcoming Dividend • Jun 13Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 20 June 2025. Payment date: 30 July 2025. Payout ratio is a comfortable 2.0% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).Reported Earnings • Jun 09Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: EPS: ₹24.66 (up from ₹23.67 in FY 2024). Revenue: ₹20.8b (up 14% from FY 2024). Net income: ₹1.36b (up 4.4% from FY 2024). Profit margin: 6.6% (down from 7.1% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • May 29+ 1 more updateRossari Biotech Limited announces Annual dividend, payable on July 30, 2025Rossari Biotech Limited announced Annual dividend of INR 0.5000 per share payable on July 30, 2025, ex-date on June 20, 2025 and record date on June 20, 2025.Reported Earnings • Apr 26Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: EPS: ₹24.66 (up from ₹23.67 in FY 2024). Revenue: ₹20.8b (up 14% from FY 2024). Net income: ₹1.36b (up 4.4% from FY 2024). Profit margin: 6.5% (down from 7.1% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 21Price target decreased by 8.8% to ₹901Down from ₹988, the current price target is an average from 3 analysts. New target price is 30% above last closing price of ₹693. Stock is down 8.1% over the past year. The company is forecast to post earnings per share of ₹24.97 for next year compared to ₹23.67 last year.お知らせ • Apr 18Rossari Biotech Limited to Report Q4, 2025 Results on Apr 25, 2025Rossari Biotech Limited announced that they will report Q4, 2025 results on Apr 25, 2025お知らせ • Jan 22Rossari Biotech Limited Approves Shifting of Registered Office of the Company, Within Local Limits of Mumbai City, Effective from February 01, 2025Rossari Biotech Limited at its board meeting held on January 21, 2025 approved shifting of the registered office of the Company within the local limits of Mumbai city from 201 A - B, 2 Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai - 400078 to Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai Maharashtra, India, 400079 effective from February 01, 2025.お知らせ • Jan 14Rossari Biotech Limited to Report Q3, 2025 Results on Jan 21, 2025Rossari Biotech Limited announced that they will report Q3, 2025 results on Jan 21, 2025Buy Or Sell Opportunity • Oct 22Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.1% to ₹786. The fair value is estimated to be ₹1,006, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 42% in 2 years. Earnings are forecast to grow by 59% in the next 2 years.お知らせ • Oct 21Rossari Biotech Limited Appoints Gurudas Aras as an Additional Director Designated as Non- Executive Independent DirectorRossari Biotech Limited appointed Mr. Gurudas Aras as an Additional Director designated as Non- Executive Independent Director with effect from October 19, 2024. Mr. Aras is the former Director of the Textile Engineering Group at A.T.E. Group and also on the advisory board and board of Studies of VJTI, Mumbai. He has more than 40 years of experience in the textile industry. Currently, he also serves as a strategic advisor to APS GmbH, a German company in the field of robotics and automation and is a Business Advisor to Rabatex Industries and Yamuna Machine Works, both from the textile engineering field. Mr. Aras holds a Bachelor's degree in Textile Engineering from Bombay University with a Gold Medal and first rank with distinction. He also earned his Master's degree in Textile Engineering in 1982, followed by a Post Graduate Diploma in Marketing Management from Bombay University in 1984. He is also a certified Crisil ESG Risk Analyst.Reported Earnings • Oct 20Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: EPS: ₹6.39 (up from ₹5.97 in 2Q 2024). Revenue: ₹4.99b (up 3.2% from 2Q 2024). Net income: ₹353.3m (up 7.2% from 2Q 2024). Profit margin: 7.1% (up from 6.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.9%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.お知らせ • Oct 11Rossari Biotech Limited to Report Q2, 2025 Results on Oct 19, 2024Rossari Biotech Limited announced that they will report Q2, 2025 results on Oct 19, 2024Price Target Changed • Sep 30Price target increased by 7.6% to ₹951Up from ₹884, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of ₹907. Stock is up 11% over the past year. The company is forecast to post earnings per share of ₹29.03 for next year compared to ₹23.67 last year.お知らせ • Aug 24Rossari Biotech Limited Approves Dividend for the Financial Year Ended 31 March, 2024Rossari Biotech Limited announced that at the AGM held on August 23, 2024, approved dividend of INR 0.50 per share for the fiscal year 2023-2024.Upcoming Dividend • Aug 09Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 16 August 2024. Payment date: 22 September 2024. Payout ratio is a comfortable 2.1% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.6%).お知らせ • Jul 22Rossari Biotech Limited, Annual General Meeting, Aug 23, 2024Rossari Biotech Limited, Annual General Meeting, Aug 23, 2024.Reported Earnings • Jul 21First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: ₹6.32 (up from ₹5.30 in 1Q 2024). Revenue: ₹4.91b (up 20% from 1Q 2024). Net income: ₹349.0m (up 19% from 1Q 2024). Profit margin: 7.1% (in line with 1Q 2024). Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) also surpassed analyst estimates by 1.6%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • Jul 13Rossari Biotech Limited to Report Q1, 2025 Results on Jul 20, 2024Rossari Biotech Limited announced that they will report Q1, 2025 results on Jul 20, 2024Reported Earnings • Apr 30Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: ₹23.67 (up from ₹19.46 in FY 2023). Revenue: ₹18.4b (up 11% from FY 2023). Net income: ₹1.31b (up 22% from FY 2023). Profit margin: 7.1% (up from 6.5% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.4%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.お知らせ • Apr 22Rossari Biotech Limited to Report Q4, 2024 Results on Apr 29, 2024Rossari Biotech Limited announced that they will report Q4, 2024 results on Apr 29, 2024Buy Or Sell Opportunity • Feb 05Now 20% undervaluedOver the last 90 days, the stock has risen 7.9% to ₹769. The fair value is estimated to be ₹962, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 34% in 2 years. Earnings are forecast to grow by 48% in the next 2 years.Price Target Changed • Jan 25Price target increased by 9.0% to ₹852Up from ₹782, the current price target is an average from 2 analysts. New target price is 9.7% above last closing price of ₹776. Stock is up 7.8% over the past year. The company is forecast to post earnings per share of ₹24.30 for next year compared to ₹19.46 last year.Reported Earnings • Jan 21Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: EPS: ₹6.23 (up from ₹4.66 in 3Q 2023). Revenue: ₹4.67b (up 20% from 3Q 2023). Net income: ₹343.9m (up 34% from 3Q 2023). Profit margin: 7.4% (up from 6.6% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 7.1%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹831, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Chemicals industry in India. Negligible returns to shareholders over past three years.Price Target Changed • Oct 28Price target decreased by 8.4% to ₹782Down from ₹854, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of ₹756. Stock is down 16% over the past year. The company is forecast to post earnings per share of ₹23.78 for next year compared to ₹19.46 last year.Reported Earnings • Oct 22Second quarter 2024 earnings released: EPS: ₹5.97 (vs ₹4.34 in 2Q 2023)Second quarter 2024 results: EPS: ₹5.97 (up from ₹4.34 in 2Q 2023). Revenue: ₹4.85b (up 14% from 2Q 2023). Net income: ₹329.5m (up 38% from 2Q 2023). Profit margin: 6.8% (up from 5.6% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 14Rossari Biotech Limited to Report Q2, 2024 Results on Oct 21, 2023Rossari Biotech Limited announced that they will report Q2, 2024 results at 4:00 PM, Indian Standard Time on Oct 21, 2023Reported Earnings • Jul 30First quarter 2024 earnings released: EPS: ₹5.30 (vs ₹5.21 in 1Q 2023)First quarter 2024 results: EPS: ₹5.30 (up from ₹5.21 in 1Q 2023). Revenue: ₹4.13b (down 5.0% from 1Q 2023). Net income: ₹292.2m (up 1.9% from 1Q 2023). Profit margin: 7.1% (up from 6.6% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 7% per year.お知らせ • Jul 25Rossari Biotech Limited to Report Q1, 2024 Results on Jul 29, 2023Rossari Biotech Limited announced that they will report Q1, 2024 results at 4:00 PM, Indian Standard Time on Jul 29, 2023お知らせ • Jul 06Rossari Biotech Limited Announces Resignation of Melier Castelino as an Independent DirectorRossari Biotech Limited announced that Ms. Meher Castelino has completed her term as an Independent Director on July 03, 2023 and consequently ceased to be the Independent Director of the Company with effect from end of day on July 03, 2023. She is a Non- Executive, Independent Director, Chairperson of Corporate Social Responsibility Committee, Member of Nomination and Remuneration Committee and Stakeholders Relationship Committee at Rossari Biotech Limited. She is a Non- Executive, Independent Director, Chairperson of Stakeholders Relationship Committee, Member of Nomination and Remuneration Committee and Corporate Social Responsibility Committee at VIP Clothing Limited. Ms. Me her Castelino automatically ceased to be a Chairperson/Member of the aforesaid Committee in Rossari Biotech Limited with effect from July 03, 2023.Valuation Update With 7 Day Price Move • Jun 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹851, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 26x in the Chemicals industry in India. Total loss to shareholders of 3.4% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₹520 per share.お知らせ • Jun 02+ 1 more updateRossari Biotech Limited Appoints Ms. Aparna Sharma , as A Non-Executive, Independent Director, Effective 29Th April, 2023Rossari Biotech Limited at its AGM held on May 31, 2023 approved appointment of Ms. Aparna Sharma (DIN: 07132341), as a Non-Executive, Independent Director of the Company for a term of Three (3) consecutive years commencing from 29th April, 2023 upto 28th April, 2026 (both days inclusive).Upcoming Dividend • May 17Upcoming dividend of ₹0.50 per share at 0.1% yieldEligible shareholders must have bought the stock before 24 May 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 2.6% and this is well supported by cash flows. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.9%).お知らせ • May 07Rossari Biotech Limited, Annual General Meeting, May 31, 2023Rossari Biotech Limited, Annual General Meeting, May 31, 2023, at 12:00 Indian Standard Time.Reported Earnings • Apr 30Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: ₹19.46 (up from ₹17.81 in FY 2022). Revenue: ₹16.6b (up 12% from FY 2022). Net income: ₹1.07b (up 9.8% from FY 2022). Profit margin: 6.5% (down from 6.6% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India.Valuation Update With 7 Day Price Move • Apr 10Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹742, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 26% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₹931 per share.Price Target Changed • Feb 07Price target decreased by 9.2% to ₹986Down from ₹1,086, the current price target is an average from 2 analysts. New target price is 44% above last closing price of ₹683. Stock is down 42% over the past year. The company is forecast to post earnings per share of ₹21.50 for next year compared to ₹17.81 last year.Reported Earnings • Feb 05Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: EPS: ₹4.66 (up from ₹4.09 in 3Q 2022). Revenue: ₹3.89b (down 9.1% from 3Q 2022). Net income: ₹256.8m (up 14% from 3Q 2022). Profit margin: 6.6% (up from 5.3% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 17%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.お知らせ • Jan 05Rossari Biotech Limited Announces Resignation of Robin Banerjee as Non-Executive Independent DirectorRossari Biotech Limited announced that Mr. Robin Banerjee, vide his letter dated January 03, 2023, has tendered his resignation as Non-Executive Independent Director of the company with effect from the close of business hours on January 03, 2023, due to pre- occupation with other work and assignments at this point of time. The reason for resignation: Mr. Robin Banerjee has tendered his resignation as a Non-Executive Independent Director of the company due to pre-occupation with other work and assignments at this point of time and there are no other material reasons for resignation other than the one mentioned in the resignation letter. Mr. Robin Banerjee was a Non-Executive, Independent Director, Nomination & Remuneration Committee (Chairperson), Audit Committee (Member), and Risk Management Committee (Member) of Rossari Biotech Limited. Mr. Robin Banerjee automatically ceased to be a Chairperson/Member of the aforesaid Committees in Rossari Biotech Limited, with effect from January 03, 2023. Mr. Robin Banerjee was a Non-Executive, Independent Director, Audit Committee (Member), Stakeholders Relationship Committee (Member), and Nomination & Remuneration Committee (Member) of VIP Clothing Limited.Board Change • Dec 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 2 highly experienced directors. Independent Director Robin Banerjee was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Major Estimate Revision • Nov 16Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 revenue forecast increased from ₹19.4b to ₹19.6b. EPS estimate fell from ₹28.49 to ₹24.40 per share. Net income forecast to grow 66% next year vs 21% growth forecast for Chemicals industry in India. Consensus price target down from ₹1,086 to ₹1,061. Share price fell 2.3% to ₹816 over the past week.Major Estimate Revision • Nov 12Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 revenue forecast increased from ₹19.4b to ₹19.6b. EPS estimate fell from ₹28.49 to ₹24.40 per share. Net income forecast to grow 66% next year vs 25% growth forecast for Chemicals industry in India. Consensus price target down from ₹1,086 to ₹1,061. Share price fell 6.8% to ₹828 over the past week.Reported Earnings • Nov 06Second quarter 2023 earnings released: EPS: ₹4.34 (vs ₹4.77 in 2Q 2022)Second quarter 2023 results: EPS: ₹4.34 (down from ₹4.77 in 2Q 2022). Revenue: ₹4.26b (up 11% from 2Q 2022). Net income: ₹239.2m (down 8.8% from 2Q 2022). Profit margin: 5.6% (down from 6.8% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.お知らせ • Oct 30Rossari Biotech Limited to Report Q2, 2023 Results on Nov 05, 2022Rossari Biotech Limited announced that they will report Q2, 2023 results on Nov 05, 2022Reported Earnings • Aug 07First quarter 2023 earnings released: EPS: ₹5.21 (vs ₹4.52 in 1Q 2022)First quarter 2023 results: EPS: ₹5.21 (up from ₹4.52 in 1Q 2022). Revenue: ₹4.35b (up 88% from 1Q 2022). Net income: ₹286.8m (up 17% from 1Q 2022). Profit margin: 6.6% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 22%, compared to a 14% growth forecast for the industry in India.お知らせ • Jul 30Rossari Biotech Limited to Report Q1, 2023 Results on Aug 06, 2022Rossari Biotech Limited announced that they will report Q1, 2023 results on Aug 06, 2022お知らせ • Jul 16Rossari Biotech Limited Approves Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022Rossari Biotech Limited at the annual general meeting held on July 15, 2022 approved to declare dividend of INR 0.50/- (25%) per equity share of the face value of INR 2/- each for the financial year ended March 31, 2022. The dividend declared at the Meeting will be credited to the Members on or after July 21, 2022 and Demand Draft shall be dispatched within the stipulated timelines.Upcoming Dividend • Jun 30Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 07 July 2022. Payment date: 14 August 2022. Payout ratio is a comfortable 2.8% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.8%). Lower than average of industry peers (0.8%).Reported Earnings • Jun 25Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: EPS: ₹17.81 (up from ₹15.56 in FY 2021). Revenue: ₹14.8b (up 109% from FY 2021). Net income: ₹976.7m (up 22% from FY 2021). Profit margin: 6.6% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Over the next year, revenue is forecast to grow 34%, compared to a 17% growth forecast for the industry in India.お知らせ • Jun 24Rossari Biotech Limited Recommended Final Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022The Directors of Rossari Biotech Limited recommended a final dividend of 25 % (that is INR 0.50) on equity shares of the face value of INR 2 each for the financial Year ended March 31, 2022. The Dividend is subject to the approval of Members at the Annual General Meeting scheduled to be held on July 15, 2022. Record date for payment of final dividend is July 8, 2022. Final dividend payout date, if approved by members is on or after July 21, 2022.Reported Earnings • May 22Full year 2022 earnings: EPS in line with analyst expectations despite revenue beatFull year 2022 results: EPS: ₹17.81 (up from ₹15.56 in FY 2021). Revenue: ₹14.9b (up 111% from FY 2021). Net income: ₹976.7m (up 22% from FY 2021). Profit margin: 6.5% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.8%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 26%, compared to a 21% growth forecast for the industry in India.お知らせ • May 21Rossari Biotech Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022Rossari Biotech Limited announced that at its board meeting held on May 19, 2022, the board approved final dividend of 25% (that is INR 0.50 per share) on equity shares of the face value of INR 2 each for the financial year ended March 31, 2022, subject To Approve the Shareholders at the upcoming Annual General Meeting ("AGM") of the company.お知らせ • May 20+ 1 more updateRossari Biotech Limited, Annual General Meeting, Jul 15, 2022Rossari Biotech Limited, Annual General Meeting, Jul 15, 2022.Price Target Changed • Apr 27Price target decreased to ₹1,252Down from ₹1,456, the current price target is an average from 2 analysts. New target price is 33% above last closing price of ₹940. Stock is down 20% over the past year. The company is forecast to post earnings per share of ₹21.55 for next year compared to ₹15.56 last year.Major Estimate Revision • Feb 21Consensus revenue estimates increase by 26%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from ₹11.8b to ₹14.8b. EPS estimate increased from ₹17.94 to ₹21.55 per share. Net income forecast to grow 55% next year vs 22% growth forecast for Chemicals industry in India. Consensus price target down from ₹1,456 to ₹1,252. Share price fell 11% to ₹1,008 over the past week.Reported Earnings • Feb 16Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: EPS: ₹4.09 (down from ₹4.16 in 3Q 2021). Revenue: ₹4.35b (up 107% from 3Q 2021). Net income: ₹225.4m (up 4.3% from 3Q 2021). Profit margin: 5.2% (down from 10% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.8%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 23%, compared to a 20% growth forecast for the industry in India.Price Target Changed • Feb 16Price target decreased to ₹1,330Down from ₹1,441, the current price target is an average from 2 analysts. New target price is 25% above last closing price of ₹1,060. Stock is up 15% over the past year. The company is forecast to post earnings per share of ₹17.94 for next year compared to ₹15.56 last year.Reported Earnings • Nov 03Second quarter 2022 earnings released: EPS ₹4.77 (vs ₹4.07 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹3.85b (up 124% from 2Q 2021). Net income: ₹262.3m (up 27% from 2Q 2021). Profit margin: 6.8% (down from 12% in 2Q 2021). The decrease in margin was driven by higher expenses.Recent Insider Transactions • Aug 08Insider recently sold ₹2.1m worth of stockOn the 4th of August, Kabir Arora sold around 2k shares on-market at roughly ₹1,415 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹3.0m more than they bought in the last 12 months.Price Target Changed • Aug 03Price target increased to ₹1,270Up from ₹1,020, the current price target is an average from 2 analysts. New target price is 8.8% below last closing price of ₹1,392. Stock is up 88% over the past year.Reported Earnings • Jul 31First quarter 2022 earnings released: EPS ₹4.52 (vs ₹3.19 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹2.34b (up 114% from 1Q 2021). Net income: ₹245.2m (up 58% from 1Q 2021). Profit margin: 11% (down from 14% in 1Q 2021). The decrease in margin was driven by higher expenses.お知らせ • Jul 16Rossari Biotech Reportedly in Advanced Talks to Acquire Specialty Chemicals BusinessRossari Biotech Limited (BSE:543213) is in advanced negotiations to acquire a Mumbai-based chemical company for INR 1,000 million to INR 1,250 million, according to multiple sources in the know. The transaction, once successful, will help Rossari to improve its high margin home, personal care, and performance chemicals (HPPC) portfolio. It will also be able to improve wallet share with existing customers by offering more products and through cross-selling. A formal announcement is expected in the next four-five days. An email sent to Rossari Biotech on July 15, 2021, did not generate any response till the press time. The target company is among the major producers of perfumery chemicals, dye Intermediates and high-tech distillation products. It caters to domestic and overseas companies in Europe, USA and Far East countries. If the current deal fructifies, it would be the company's second acquisition this fiscal year. It had acquired Unitop Chemicals for INR 4,210 million in June 2021.お知らせ • Jun 03Rossari Biotech Limited (BSE:543213) entered in an agreement to acquire Unitop Chemicals Pvt. Ltd. for approximately INR 4.2 billion.Rossari Biotech Limited (BSE:543213) entered in an agreement to acquire Unitop Chemicals Pvt. Ltd. for approximately INR 4.2 billion on June 2, 2021. Rossari plans to fund the investment through cash on balance sheet and doesn’t intend to raise any debt for this acquisition. In the fiscal year 2020, Unitop Chemicals’ revenues stood at INR 2.80 billion, with adjusted EBITDA at INR 430 million. As per the agreement Rossari will be acquiring 100% of the equity capital of Unitop Chemicals. 65% equity share capital in the first tranche, which is expected to be completed by the second quarter of fiscal year 2022. The remaining part 35% of the acquisition is expected to close in 2023-2024 . Axcelus Finserv Private Limited was the sole advisor to Rossari for the transaction. Shardul Amarchand Mangaldas acted as the legal counsel and KPMG assisted in financial and tax due diligence. Wodehouse Capital Advisors Private Ltd. acted as the financial advisor to Unitop Chemicals Pvt. Ltd.Reported Earnings • May 15Full year 2021 earnings released: EPS ₹15.56 (vs ₹13.42 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2021 results: Revenue: ₹7.19b (up 20% from FY 2020). Net income: ₹802.2m (up 23% from FY 2020). Profit margin: 11% (in line with FY 2020).お知らせ • Mar 25Rossari Biotech Limited announced that it expects to receive INR 2.999997816 billion in funding from Malabar Investments, LLC, State Bank of India, Asset Management Arm and other investorsRossari Biotech Limited (BSE:543213) announced a private placement of 3,012,046 common shares at a price of INR 996 per share for gross proceeds of INR 2,999,997,816 on March 23, 2021. The shares carry a face value of INR 2 per share. The shares will be issued at a premium. The shares will be issued on preferential allotment basis. The transaction will include participation from returning investor SBI Mutual Fund; a fund managed by State Bank of India, Asset Management Arm for 1,004,016 shares, new investor Malabar Select Fund; a fund managed by returning investor Malabar Investments, LLC for 391,556 shares, returning investor Malabar Value Fund; a fund managed by Malabar Investments, LLC for 90,361 shares, returning investor Malabar India Fund Limited; a fund managed by Malabar Investments, LLC for 271,084 shares, lndia Acom Fund Ltd for 351,405 shares, individual investors Ramesh Siyani for 451,807 shares and Arpit Kbandelwal for 451,807 shares. Post the closing of the transaction, SBI Mutual Fund's shareholding will change from 5.51% to 7.04%, Ramesh Sayani will hold 0.82%, Arpit Khandelwal will hold 0.82%, Malabar India Fund Limited's shareholding will change from 1.23% to 1.66%, Malabar Select Fund will hold 0.71%, Malabar Value Fund's shareholding will change from 0.10% to 0.26% and lndia Acom Fund Ltd's sharehloding will change from 0.68% to 1.28%. The transaction is subject to the approval of the shareholders of the company at Extra Ordinary General Meeting to be held on April 17, 2021 and is subject to the approval of the regulatory/ statutory authorities as may be applicable. The transaction was approved by the board codirectors of the company.Is New 90 Day High Low • Feb 20New 90-day high: ₹1,036The company is up 31% from its price of ₹789 on 20 November 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period.Reported Earnings • Jan 24Third quarter 2021 earnings released: EPS ₹4.16The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ₹2.11b (up 31% from 3Q 2020). Net income: ₹216.0m (up 30% from 3Q 2020). Profit margin: 10% (in line with 3Q 2020).お知らせ • Jan 16Rossari Biotech Limited to Report Q3, 2021 Results on Jan 23, 2021Rossari Biotech Limited announced that they will report Q3, 2021 results on Jan 23, 2021Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹995, the stock is trading at a trailing P/E ratio of 71.3x, up from the previous P/E ratio of 61.6x. This compares to an average P/E of 18x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹954, the stock is trading at a trailing P/E ratio of 68.4x, up from the previous P/E ratio of 59.2x. This compares to an average P/E of 17x in the Chemicals industry in India.Is New 90 Day High Low • Dec 22New 90-day high: ₹859The company is up 11% from its price of ₹771 on 23 September 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.Is New 90 Day High Low • Dec 03New 90-day high: ₹839The company is up 6.0% from its price of ₹793 on 04 September 2020. The Indian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.Reported Earnings • Oct 25First half earnings releasedOver the last 12 months the company has reported total profits of ₹695.5m, up 25% from the prior year. Total revenue was ₹6.07b over the last 12 months, up 8.7% from the prior year.お知らせ • Oct 20Rossari Biotech Limited to Report Q2, 2021 Results on Oct 24, 2020Rossari Biotech Limited announced that they will report Q2, 2021 results on Oct 24, 2020業績と収益の成長予測BSE:543213 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202829,7291,8611,621N/A43/31/202726,5221,4991,123N/A26/30/202625,4981,507N/AN/AN/A3/31/202623,9641,492-1,996651N/A12/31/202522,9111,377N/AN/AN/A9/30/202522,2211,366-1,690731N/A6/30/202521,3441,351N/AN/AN/A3/31/202520,8031,364-2111,374N/A12/31/202419,7341,361N/AN/AN/A9/30/202419,2451,388171,162N/A6/30/202419,0961,364N/AN/AN/A3/31/202418,3061,307-880433N/A12/31/202317,6431,255N/AN/AN/A9/30/202316,8981,168-341631N/A6/30/202316,3181,078N/AN/AN/A3/31/202316,5591,0731,1871,516N/A12/31/202216,8831,027N/AN/AN/A9/30/202217,275995729990N/A6/30/202216,8661,018N/AN/AN/A3/31/202214,830977-89294N/A12/31/202112,623957N/AN/AN/A9/30/202110,438948-342129N/A6/30/20218,310892N/AN/AN/A3/31/20217,093802-103478N/A12/31/20206,507729N/AN/AN/A9/30/20206,0316951981,045N/A6/30/20205,818666N/AN/AN/A3/31/20206,001653N/A568N/A3/31/20195,162457N/A712N/A3/31/20182,922254N/A254N/A3/31/20172,350143N/A67N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 543213の予測収益成長率 (年間12.9% ) は 貯蓄率 ( 6.9% ) を上回っています。収益対市場: 543213の収益 ( 12.9% ) Indian市場 ( 16.8% ) よりも低い成長が予測されています。高成長収益: 543213の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 543213の収益 ( 9% ) Indian市場 ( 11.2% ) よりも低い成長が予測されています。高い収益成長: 543213の収益 ( 9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 543213の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/22 22:15終値2026/08/21 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Rossari Biotech Limited 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関null nullAnand Rathi Shares and Stock Brokers LimitedNitesh DhootAnand Rathi Shares and Stock Brokers LimitedAbhishek NavalgundCentrum Broking Limited2 その他のアナリストを表示
Price Target Changed • Jan 20Price target decreased by 20% to ₹680Down from ₹851, the current price target is an average from 3 analysts. New target price is 34% above last closing price of ₹509. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₹25.10 for next year compared to ₹24.66 last year.
Price Target Changed • Apr 21Price target decreased by 8.8% to ₹901Down from ₹988, the current price target is an average from 3 analysts. New target price is 30% above last closing price of ₹693. Stock is down 8.1% over the past year. The company is forecast to post earnings per share of ₹24.97 for next year compared to ₹23.67 last year.
Price Target Changed • Sep 30Price target increased by 7.6% to ₹951Up from ₹884, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of ₹907. Stock is up 11% over the past year. The company is forecast to post earnings per share of ₹29.03 for next year compared to ₹23.67 last year.
Price Target Changed • Jan 25Price target increased by 9.0% to ₹852Up from ₹782, the current price target is an average from 2 analysts. New target price is 9.7% above last closing price of ₹776. Stock is up 7.8% over the past year. The company is forecast to post earnings per share of ₹24.30 for next year compared to ₹19.46 last year.
Price Target Changed • Oct 28Price target decreased by 8.4% to ₹782Down from ₹854, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of ₹756. Stock is down 16% over the past year. The company is forecast to post earnings per share of ₹23.78 for next year compared to ₹19.46 last year.
Price Target Changed • Feb 07Price target decreased by 9.2% to ₹986Down from ₹1,086, the current price target is an average from 2 analysts. New target price is 44% above last closing price of ₹683. Stock is down 42% over the past year. The company is forecast to post earnings per share of ₹21.50 for next year compared to ₹17.81 last year.
お知らせ • Jul 21Rossari Biotech Limited Approves Dividend for the Financial Year Ended 31 March 2026Rossari Biotech Limited at its Annual General Meeting held on July 20, 2026, approved dividend of INR 0.50 (25%) per Equity Share of the face value of INR 2 each for the Financial Year ended 31 March 2026.
お知らせ • Jul 11Rossari Biotech Limited to Report Q1, 2027 Results on Jul 18, 2026Rossari Biotech Limited announced that they will report Q1, 2027 results at 12:08 PM, Indian Standard Time on Jul 18, 2026
お知らせ • Jun 18Rossari Biotech Limited, Annual General Meeting, Jul 20, 2026Rossari Biotech Limited, Annual General Meeting, Jul 20, 2026, at 11:00 Indian Standard Time.
Reported Earnings • Apr 29Full year 2026 earnings: EPS and revenues exceed analyst expectationsFull year 2026 results: EPS: ₹26.95 (up from ₹24.66 in FY 2025). Revenue: ₹24.2b (up 16% from FY 2025). Net income: ₹1.49b (up 9.4% from FY 2025). Profit margin: 6.2% (down from 6.6% in FY 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.5%. Earnings per share (EPS) also surpassed analyst estimates by 7.0%. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹513, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 28x in the Chemicals industry in India. Total loss to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹310 per share.
お知らせ • Apr 19Rossari Biotech Limited to Report Q4, 2026 Results on Apr 27, 2026Rossari Biotech Limited announced that they will report Q4, 2026 results on Apr 27, 2026
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹447, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 26x in the Chemicals industry in India. Total loss to shareholders of 40% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹324 per share.
Price Target Changed • Jan 20Price target decreased by 20% to ₹680Down from ₹851, the current price target is an average from 3 analysts. New target price is 34% above last closing price of ₹509. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₹25.10 for next year compared to ₹24.66 last year.
Reported Earnings • Jan 18Third quarter 2026 earnings: EPS misses analyst expectationsThird quarter 2026 results: EPS: ₹5.92 (up from ₹5.73 in 3Q 2025). Revenue: ₹5.82b (up 14% from 3Q 2025). Net income: ₹327.7m (up 3.4% from 3Q 2025). Profit margin: 5.6% (down from 6.2% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 4.7%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Jan 10Rossari Biotech Limited to Report Q3, 2026 Results on Jan 17, 2026Rossari Biotech Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Jan 17, 2026
Reported Earnings • Oct 16Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: ₹6.66 (up from ₹6.39 in 2Q 2025). Revenue: ₹5.88b (up 18% from 2Q 2025). Net income: ₹368.8m (up 4.4% from 2Q 2025). Profit margin: 6.3% (down from 7.1% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.7%. Earnings per share (EPS) also surpassed analyst estimates by 3.9%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Oct 07Rossari Biotech Limited to Report Q2, 2026 Results on Oct 15, 2025Rossari Biotech Limited announced that they will report Q2, 2026 results at 12:08 PM, Indian Standard Time on Oct 15, 2025
Reported Earnings • Jul 21First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: EPS: ₹6.07 (down from ₹6.32 in 1Q 2025). Revenue: ₹5.45b (up 11% from 1Q 2025). Net income: ₹336.0m (down 3.7% from 1Q 2025). Profit margin: 6.2% (down from 7.1% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) exceeded analyst estimates by 12%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Jul 15Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 8.0% to ₹743. The fair value is estimated to be ₹596, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.6% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 54% in the next 2 years.
お知らせ • Jul 11Rossari Biotech Limited to Report Q1, 2026 Results on Jul 19, 2025Rossari Biotech Limited announced that they will report Q1, 2026 results at 12:08 PM, Indian Standard Time on Jul 19, 2025
Upcoming Dividend • Jun 13Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 20 June 2025. Payment date: 30 July 2025. Payout ratio is a comfortable 2.0% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).
Reported Earnings • Jun 09Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: EPS: ₹24.66 (up from ₹23.67 in FY 2024). Revenue: ₹20.8b (up 14% from FY 2024). Net income: ₹1.36b (up 4.4% from FY 2024). Profit margin: 6.6% (down from 7.1% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • May 29+ 1 more updateRossari Biotech Limited announces Annual dividend, payable on July 30, 2025Rossari Biotech Limited announced Annual dividend of INR 0.5000 per share payable on July 30, 2025, ex-date on June 20, 2025 and record date on June 20, 2025.
Reported Earnings • Apr 26Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: EPS: ₹24.66 (up from ₹23.67 in FY 2024). Revenue: ₹20.8b (up 14% from FY 2024). Net income: ₹1.36b (up 4.4% from FY 2024). Profit margin: 6.5% (down from 7.1% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 21Price target decreased by 8.8% to ₹901Down from ₹988, the current price target is an average from 3 analysts. New target price is 30% above last closing price of ₹693. Stock is down 8.1% over the past year. The company is forecast to post earnings per share of ₹24.97 for next year compared to ₹23.67 last year.
お知らせ • Apr 18Rossari Biotech Limited to Report Q4, 2025 Results on Apr 25, 2025Rossari Biotech Limited announced that they will report Q4, 2025 results on Apr 25, 2025
お知らせ • Jan 22Rossari Biotech Limited Approves Shifting of Registered Office of the Company, Within Local Limits of Mumbai City, Effective from February 01, 2025Rossari Biotech Limited at its board meeting held on January 21, 2025 approved shifting of the registered office of the Company within the local limits of Mumbai city from 201 A - B, 2 Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai - 400078 to Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai Maharashtra, India, 400079 effective from February 01, 2025.
お知らせ • Jan 14Rossari Biotech Limited to Report Q3, 2025 Results on Jan 21, 2025Rossari Biotech Limited announced that they will report Q3, 2025 results on Jan 21, 2025
Buy Or Sell Opportunity • Oct 22Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.1% to ₹786. The fair value is estimated to be ₹1,006, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 42% in 2 years. Earnings are forecast to grow by 59% in the next 2 years.
お知らせ • Oct 21Rossari Biotech Limited Appoints Gurudas Aras as an Additional Director Designated as Non- Executive Independent DirectorRossari Biotech Limited appointed Mr. Gurudas Aras as an Additional Director designated as Non- Executive Independent Director with effect from October 19, 2024. Mr. Aras is the former Director of the Textile Engineering Group at A.T.E. Group and also on the advisory board and board of Studies of VJTI, Mumbai. He has more than 40 years of experience in the textile industry. Currently, he also serves as a strategic advisor to APS GmbH, a German company in the field of robotics and automation and is a Business Advisor to Rabatex Industries and Yamuna Machine Works, both from the textile engineering field. Mr. Aras holds a Bachelor's degree in Textile Engineering from Bombay University with a Gold Medal and first rank with distinction. He also earned his Master's degree in Textile Engineering in 1982, followed by a Post Graduate Diploma in Marketing Management from Bombay University in 1984. He is also a certified Crisil ESG Risk Analyst.
Reported Earnings • Oct 20Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: EPS: ₹6.39 (up from ₹5.97 in 2Q 2024). Revenue: ₹4.99b (up 3.2% from 2Q 2024). Net income: ₹353.3m (up 7.2% from 2Q 2024). Profit margin: 7.1% (up from 6.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.9%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
お知らせ • Oct 11Rossari Biotech Limited to Report Q2, 2025 Results on Oct 19, 2024Rossari Biotech Limited announced that they will report Q2, 2025 results on Oct 19, 2024
Price Target Changed • Sep 30Price target increased by 7.6% to ₹951Up from ₹884, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of ₹907. Stock is up 11% over the past year. The company is forecast to post earnings per share of ₹29.03 for next year compared to ₹23.67 last year.
お知らせ • Aug 24Rossari Biotech Limited Approves Dividend for the Financial Year Ended 31 March, 2024Rossari Biotech Limited announced that at the AGM held on August 23, 2024, approved dividend of INR 0.50 per share for the fiscal year 2023-2024.
Upcoming Dividend • Aug 09Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 16 August 2024. Payment date: 22 September 2024. Payout ratio is a comfortable 2.1% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.6%).
お知らせ • Jul 22Rossari Biotech Limited, Annual General Meeting, Aug 23, 2024Rossari Biotech Limited, Annual General Meeting, Aug 23, 2024.
Reported Earnings • Jul 21First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: ₹6.32 (up from ₹5.30 in 1Q 2024). Revenue: ₹4.91b (up 20% from 1Q 2024). Net income: ₹349.0m (up 19% from 1Q 2024). Profit margin: 7.1% (in line with 1Q 2024). Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) also surpassed analyst estimates by 1.6%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • Jul 13Rossari Biotech Limited to Report Q1, 2025 Results on Jul 20, 2024Rossari Biotech Limited announced that they will report Q1, 2025 results on Jul 20, 2024
Reported Earnings • Apr 30Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: ₹23.67 (up from ₹19.46 in FY 2023). Revenue: ₹18.4b (up 11% from FY 2023). Net income: ₹1.31b (up 22% from FY 2023). Profit margin: 7.1% (up from 6.5% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.4%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
お知らせ • Apr 22Rossari Biotech Limited to Report Q4, 2024 Results on Apr 29, 2024Rossari Biotech Limited announced that they will report Q4, 2024 results on Apr 29, 2024
Buy Or Sell Opportunity • Feb 05Now 20% undervaluedOver the last 90 days, the stock has risen 7.9% to ₹769. The fair value is estimated to be ₹962, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 34% in 2 years. Earnings are forecast to grow by 48% in the next 2 years.
Price Target Changed • Jan 25Price target increased by 9.0% to ₹852Up from ₹782, the current price target is an average from 2 analysts. New target price is 9.7% above last closing price of ₹776. Stock is up 7.8% over the past year. The company is forecast to post earnings per share of ₹24.30 for next year compared to ₹19.46 last year.
Reported Earnings • Jan 21Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: EPS: ₹6.23 (up from ₹4.66 in 3Q 2023). Revenue: ₹4.67b (up 20% from 3Q 2023). Net income: ₹343.9m (up 34% from 3Q 2023). Profit margin: 7.4% (up from 6.6% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 7.1%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹831, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Chemicals industry in India. Negligible returns to shareholders over past three years.
Price Target Changed • Oct 28Price target decreased by 8.4% to ₹782Down from ₹854, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of ₹756. Stock is down 16% over the past year. The company is forecast to post earnings per share of ₹23.78 for next year compared to ₹19.46 last year.
Reported Earnings • Oct 22Second quarter 2024 earnings released: EPS: ₹5.97 (vs ₹4.34 in 2Q 2023)Second quarter 2024 results: EPS: ₹5.97 (up from ₹4.34 in 2Q 2023). Revenue: ₹4.85b (up 14% from 2Q 2023). Net income: ₹329.5m (up 38% from 2Q 2023). Profit margin: 6.8% (up from 5.6% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 14Rossari Biotech Limited to Report Q2, 2024 Results on Oct 21, 2023Rossari Biotech Limited announced that they will report Q2, 2024 results at 4:00 PM, Indian Standard Time on Oct 21, 2023
Reported Earnings • Jul 30First quarter 2024 earnings released: EPS: ₹5.30 (vs ₹5.21 in 1Q 2023)First quarter 2024 results: EPS: ₹5.30 (up from ₹5.21 in 1Q 2023). Revenue: ₹4.13b (down 5.0% from 1Q 2023). Net income: ₹292.2m (up 1.9% from 1Q 2023). Profit margin: 7.1% (up from 6.6% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 7% per year.
お知らせ • Jul 25Rossari Biotech Limited to Report Q1, 2024 Results on Jul 29, 2023Rossari Biotech Limited announced that they will report Q1, 2024 results at 4:00 PM, Indian Standard Time on Jul 29, 2023
お知らせ • Jul 06Rossari Biotech Limited Announces Resignation of Melier Castelino as an Independent DirectorRossari Biotech Limited announced that Ms. Meher Castelino has completed her term as an Independent Director on July 03, 2023 and consequently ceased to be the Independent Director of the Company with effect from end of day on July 03, 2023. She is a Non- Executive, Independent Director, Chairperson of Corporate Social Responsibility Committee, Member of Nomination and Remuneration Committee and Stakeholders Relationship Committee at Rossari Biotech Limited. She is a Non- Executive, Independent Director, Chairperson of Stakeholders Relationship Committee, Member of Nomination and Remuneration Committee and Corporate Social Responsibility Committee at VIP Clothing Limited. Ms. Me her Castelino automatically ceased to be a Chairperson/Member of the aforesaid Committee in Rossari Biotech Limited with effect from July 03, 2023.
Valuation Update With 7 Day Price Move • Jun 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹851, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 26x in the Chemicals industry in India. Total loss to shareholders of 3.4% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₹520 per share.
お知らせ • Jun 02+ 1 more updateRossari Biotech Limited Appoints Ms. Aparna Sharma , as A Non-Executive, Independent Director, Effective 29Th April, 2023Rossari Biotech Limited at its AGM held on May 31, 2023 approved appointment of Ms. Aparna Sharma (DIN: 07132341), as a Non-Executive, Independent Director of the Company for a term of Three (3) consecutive years commencing from 29th April, 2023 upto 28th April, 2026 (both days inclusive).
Upcoming Dividend • May 17Upcoming dividend of ₹0.50 per share at 0.1% yieldEligible shareholders must have bought the stock before 24 May 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 2.6% and this is well supported by cash flows. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.9%).
お知らせ • May 07Rossari Biotech Limited, Annual General Meeting, May 31, 2023Rossari Biotech Limited, Annual General Meeting, May 31, 2023, at 12:00 Indian Standard Time.
Reported Earnings • Apr 30Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: ₹19.46 (up from ₹17.81 in FY 2022). Revenue: ₹16.6b (up 12% from FY 2022). Net income: ₹1.07b (up 9.8% from FY 2022). Profit margin: 6.5% (down from 6.6% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Apr 10Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹742, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 26% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₹931 per share.
Price Target Changed • Feb 07Price target decreased by 9.2% to ₹986Down from ₹1,086, the current price target is an average from 2 analysts. New target price is 44% above last closing price of ₹683. Stock is down 42% over the past year. The company is forecast to post earnings per share of ₹21.50 for next year compared to ₹17.81 last year.
Reported Earnings • Feb 05Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: EPS: ₹4.66 (up from ₹4.09 in 3Q 2022). Revenue: ₹3.89b (down 9.1% from 3Q 2022). Net income: ₹256.8m (up 14% from 3Q 2022). Profit margin: 6.6% (up from 5.3% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 17%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.
お知らせ • Jan 05Rossari Biotech Limited Announces Resignation of Robin Banerjee as Non-Executive Independent DirectorRossari Biotech Limited announced that Mr. Robin Banerjee, vide his letter dated January 03, 2023, has tendered his resignation as Non-Executive Independent Director of the company with effect from the close of business hours on January 03, 2023, due to pre- occupation with other work and assignments at this point of time. The reason for resignation: Mr. Robin Banerjee has tendered his resignation as a Non-Executive Independent Director of the company due to pre-occupation with other work and assignments at this point of time and there are no other material reasons for resignation other than the one mentioned in the resignation letter. Mr. Robin Banerjee was a Non-Executive, Independent Director, Nomination & Remuneration Committee (Chairperson), Audit Committee (Member), and Risk Management Committee (Member) of Rossari Biotech Limited. Mr. Robin Banerjee automatically ceased to be a Chairperson/Member of the aforesaid Committees in Rossari Biotech Limited, with effect from January 03, 2023. Mr. Robin Banerjee was a Non-Executive, Independent Director, Audit Committee (Member), Stakeholders Relationship Committee (Member), and Nomination & Remuneration Committee (Member) of VIP Clothing Limited.
Board Change • Dec 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 2 highly experienced directors. Independent Director Robin Banerjee was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Major Estimate Revision • Nov 16Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 revenue forecast increased from ₹19.4b to ₹19.6b. EPS estimate fell from ₹28.49 to ₹24.40 per share. Net income forecast to grow 66% next year vs 21% growth forecast for Chemicals industry in India. Consensus price target down from ₹1,086 to ₹1,061. Share price fell 2.3% to ₹816 over the past week.
Major Estimate Revision • Nov 12Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 revenue forecast increased from ₹19.4b to ₹19.6b. EPS estimate fell from ₹28.49 to ₹24.40 per share. Net income forecast to grow 66% next year vs 25% growth forecast for Chemicals industry in India. Consensus price target down from ₹1,086 to ₹1,061. Share price fell 6.8% to ₹828 over the past week.
Reported Earnings • Nov 06Second quarter 2023 earnings released: EPS: ₹4.34 (vs ₹4.77 in 2Q 2022)Second quarter 2023 results: EPS: ₹4.34 (down from ₹4.77 in 2Q 2022). Revenue: ₹4.26b (up 11% from 2Q 2022). Net income: ₹239.2m (down 8.8% from 2Q 2022). Profit margin: 5.6% (down from 6.8% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.
お知らせ • Oct 30Rossari Biotech Limited to Report Q2, 2023 Results on Nov 05, 2022Rossari Biotech Limited announced that they will report Q2, 2023 results on Nov 05, 2022
Reported Earnings • Aug 07First quarter 2023 earnings released: EPS: ₹5.21 (vs ₹4.52 in 1Q 2022)First quarter 2023 results: EPS: ₹5.21 (up from ₹4.52 in 1Q 2022). Revenue: ₹4.35b (up 88% from 1Q 2022). Net income: ₹286.8m (up 17% from 1Q 2022). Profit margin: 6.6% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 22%, compared to a 14% growth forecast for the industry in India.
お知らせ • Jul 30Rossari Biotech Limited to Report Q1, 2023 Results on Aug 06, 2022Rossari Biotech Limited announced that they will report Q1, 2023 results on Aug 06, 2022
お知らせ • Jul 16Rossari Biotech Limited Approves Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022Rossari Biotech Limited at the annual general meeting held on July 15, 2022 approved to declare dividend of INR 0.50/- (25%) per equity share of the face value of INR 2/- each for the financial year ended March 31, 2022. The dividend declared at the Meeting will be credited to the Members on or after July 21, 2022 and Demand Draft shall be dispatched within the stipulated timelines.
Upcoming Dividend • Jun 30Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 07 July 2022. Payment date: 14 August 2022. Payout ratio is a comfortable 2.8% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.8%). Lower than average of industry peers (0.8%).
Reported Earnings • Jun 25Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: EPS: ₹17.81 (up from ₹15.56 in FY 2021). Revenue: ₹14.8b (up 109% from FY 2021). Net income: ₹976.7m (up 22% from FY 2021). Profit margin: 6.6% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Over the next year, revenue is forecast to grow 34%, compared to a 17% growth forecast for the industry in India.
お知らせ • Jun 24Rossari Biotech Limited Recommended Final Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022The Directors of Rossari Biotech Limited recommended a final dividend of 25 % (that is INR 0.50) on equity shares of the face value of INR 2 each for the financial Year ended March 31, 2022. The Dividend is subject to the approval of Members at the Annual General Meeting scheduled to be held on July 15, 2022. Record date for payment of final dividend is July 8, 2022. Final dividend payout date, if approved by members is on or after July 21, 2022.
Reported Earnings • May 22Full year 2022 earnings: EPS in line with analyst expectations despite revenue beatFull year 2022 results: EPS: ₹17.81 (up from ₹15.56 in FY 2021). Revenue: ₹14.9b (up 111% from FY 2021). Net income: ₹976.7m (up 22% from FY 2021). Profit margin: 6.5% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.8%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 26%, compared to a 21% growth forecast for the industry in India.
お知らせ • May 21Rossari Biotech Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022Rossari Biotech Limited announced that at its board meeting held on May 19, 2022, the board approved final dividend of 25% (that is INR 0.50 per share) on equity shares of the face value of INR 2 each for the financial year ended March 31, 2022, subject To Approve the Shareholders at the upcoming Annual General Meeting ("AGM") of the company.
お知らせ • May 20+ 1 more updateRossari Biotech Limited, Annual General Meeting, Jul 15, 2022Rossari Biotech Limited, Annual General Meeting, Jul 15, 2022.
Price Target Changed • Apr 27Price target decreased to ₹1,252Down from ₹1,456, the current price target is an average from 2 analysts. New target price is 33% above last closing price of ₹940. Stock is down 20% over the past year. The company is forecast to post earnings per share of ₹21.55 for next year compared to ₹15.56 last year.
Major Estimate Revision • Feb 21Consensus revenue estimates increase by 26%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from ₹11.8b to ₹14.8b. EPS estimate increased from ₹17.94 to ₹21.55 per share. Net income forecast to grow 55% next year vs 22% growth forecast for Chemicals industry in India. Consensus price target down from ₹1,456 to ₹1,252. Share price fell 11% to ₹1,008 over the past week.
Reported Earnings • Feb 16Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: EPS: ₹4.09 (down from ₹4.16 in 3Q 2021). Revenue: ₹4.35b (up 107% from 3Q 2021). Net income: ₹225.4m (up 4.3% from 3Q 2021). Profit margin: 5.2% (down from 10% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.8%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 23%, compared to a 20% growth forecast for the industry in India.
Price Target Changed • Feb 16Price target decreased to ₹1,330Down from ₹1,441, the current price target is an average from 2 analysts. New target price is 25% above last closing price of ₹1,060. Stock is up 15% over the past year. The company is forecast to post earnings per share of ₹17.94 for next year compared to ₹15.56 last year.
Reported Earnings • Nov 03Second quarter 2022 earnings released: EPS ₹4.77 (vs ₹4.07 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹3.85b (up 124% from 2Q 2021). Net income: ₹262.3m (up 27% from 2Q 2021). Profit margin: 6.8% (down from 12% in 2Q 2021). The decrease in margin was driven by higher expenses.
Recent Insider Transactions • Aug 08Insider recently sold ₹2.1m worth of stockOn the 4th of August, Kabir Arora sold around 2k shares on-market at roughly ₹1,415 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹3.0m more than they bought in the last 12 months.
Price Target Changed • Aug 03Price target increased to ₹1,270Up from ₹1,020, the current price target is an average from 2 analysts. New target price is 8.8% below last closing price of ₹1,392. Stock is up 88% over the past year.
Reported Earnings • Jul 31First quarter 2022 earnings released: EPS ₹4.52 (vs ₹3.19 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹2.34b (up 114% from 1Q 2021). Net income: ₹245.2m (up 58% from 1Q 2021). Profit margin: 11% (down from 14% in 1Q 2021). The decrease in margin was driven by higher expenses.
お知らせ • Jul 16Rossari Biotech Reportedly in Advanced Talks to Acquire Specialty Chemicals BusinessRossari Biotech Limited (BSE:543213) is in advanced negotiations to acquire a Mumbai-based chemical company for INR 1,000 million to INR 1,250 million, according to multiple sources in the know. The transaction, once successful, will help Rossari to improve its high margin home, personal care, and performance chemicals (HPPC) portfolio. It will also be able to improve wallet share with existing customers by offering more products and through cross-selling. A formal announcement is expected in the next four-five days. An email sent to Rossari Biotech on July 15, 2021, did not generate any response till the press time. The target company is among the major producers of perfumery chemicals, dye Intermediates and high-tech distillation products. It caters to domestic and overseas companies in Europe, USA and Far East countries. If the current deal fructifies, it would be the company's second acquisition this fiscal year. It had acquired Unitop Chemicals for INR 4,210 million in June 2021.
お知らせ • Jun 03Rossari Biotech Limited (BSE:543213) entered in an agreement to acquire Unitop Chemicals Pvt. Ltd. for approximately INR 4.2 billion.Rossari Biotech Limited (BSE:543213) entered in an agreement to acquire Unitop Chemicals Pvt. Ltd. for approximately INR 4.2 billion on June 2, 2021. Rossari plans to fund the investment through cash on balance sheet and doesn’t intend to raise any debt for this acquisition. In the fiscal year 2020, Unitop Chemicals’ revenues stood at INR 2.80 billion, with adjusted EBITDA at INR 430 million. As per the agreement Rossari will be acquiring 100% of the equity capital of Unitop Chemicals. 65% equity share capital in the first tranche, which is expected to be completed by the second quarter of fiscal year 2022. The remaining part 35% of the acquisition is expected to close in 2023-2024 . Axcelus Finserv Private Limited was the sole advisor to Rossari for the transaction. Shardul Amarchand Mangaldas acted as the legal counsel and KPMG assisted in financial and tax due diligence. Wodehouse Capital Advisors Private Ltd. acted as the financial advisor to Unitop Chemicals Pvt. Ltd.
Reported Earnings • May 15Full year 2021 earnings released: EPS ₹15.56 (vs ₹13.42 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2021 results: Revenue: ₹7.19b (up 20% from FY 2020). Net income: ₹802.2m (up 23% from FY 2020). Profit margin: 11% (in line with FY 2020).
お知らせ • Mar 25Rossari Biotech Limited announced that it expects to receive INR 2.999997816 billion in funding from Malabar Investments, LLC, State Bank of India, Asset Management Arm and other investorsRossari Biotech Limited (BSE:543213) announced a private placement of 3,012,046 common shares at a price of INR 996 per share for gross proceeds of INR 2,999,997,816 on March 23, 2021. The shares carry a face value of INR 2 per share. The shares will be issued at a premium. The shares will be issued on preferential allotment basis. The transaction will include participation from returning investor SBI Mutual Fund; a fund managed by State Bank of India, Asset Management Arm for 1,004,016 shares, new investor Malabar Select Fund; a fund managed by returning investor Malabar Investments, LLC for 391,556 shares, returning investor Malabar Value Fund; a fund managed by Malabar Investments, LLC for 90,361 shares, returning investor Malabar India Fund Limited; a fund managed by Malabar Investments, LLC for 271,084 shares, lndia Acom Fund Ltd for 351,405 shares, individual investors Ramesh Siyani for 451,807 shares and Arpit Kbandelwal for 451,807 shares. Post the closing of the transaction, SBI Mutual Fund's shareholding will change from 5.51% to 7.04%, Ramesh Sayani will hold 0.82%, Arpit Khandelwal will hold 0.82%, Malabar India Fund Limited's shareholding will change from 1.23% to 1.66%, Malabar Select Fund will hold 0.71%, Malabar Value Fund's shareholding will change from 0.10% to 0.26% and lndia Acom Fund Ltd's sharehloding will change from 0.68% to 1.28%. The transaction is subject to the approval of the shareholders of the company at Extra Ordinary General Meeting to be held on April 17, 2021 and is subject to the approval of the regulatory/ statutory authorities as may be applicable. The transaction was approved by the board codirectors of the company.
Is New 90 Day High Low • Feb 20New 90-day high: ₹1,036The company is up 31% from its price of ₹789 on 20 November 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period.
Reported Earnings • Jan 24Third quarter 2021 earnings released: EPS ₹4.16The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ₹2.11b (up 31% from 3Q 2020). Net income: ₹216.0m (up 30% from 3Q 2020). Profit margin: 10% (in line with 3Q 2020).
お知らせ • Jan 16Rossari Biotech Limited to Report Q3, 2021 Results on Jan 23, 2021Rossari Biotech Limited announced that they will report Q3, 2021 results on Jan 23, 2021
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹995, the stock is trading at a trailing P/E ratio of 71.3x, up from the previous P/E ratio of 61.6x. This compares to an average P/E of 18x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹954, the stock is trading at a trailing P/E ratio of 68.4x, up from the previous P/E ratio of 59.2x. This compares to an average P/E of 17x in the Chemicals industry in India.
Is New 90 Day High Low • Dec 22New 90-day high: ₹859The company is up 11% from its price of ₹771 on 23 September 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.
Is New 90 Day High Low • Dec 03New 90-day high: ₹839The company is up 6.0% from its price of ₹793 on 04 September 2020. The Indian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.
Reported Earnings • Oct 25First half earnings releasedOver the last 12 months the company has reported total profits of ₹695.5m, up 25% from the prior year. Total revenue was ₹6.07b over the last 12 months, up 8.7% from the prior year.
お知らせ • Oct 20Rossari Biotech Limited to Report Q2, 2021 Results on Oct 24, 2020Rossari Biotech Limited announced that they will report Q2, 2021 results on Oct 24, 2020